Ledipasvir/sofosbuvir (Harvoni): Improving options for hepatitis C virus infection

P and T

Volumn 40, Issue 4, 2015, Pages 256-276

  Diana, Gritsenko ^a   Gregory, Hughes ^b  

^a LONG ISLAND UNIVERSITY   (United States)

^b ST JOHN'S UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ANTIMYCOBACTERIAL AGENT; BREAST CANCER RESISTANCE PROTEIN; CARBAMAZEPINE; DASABUVIR; LEDIPASVIR PLUS SOFOSBUVIR; MULTIDRUG RESISTANCE PROTEIN; OMBITASVIR; PARITAPREVIR; PHENYTOIN; PROTON PUMP INHIBITOR; RIBAVIRIN; RIFABUTIN; RIFAPENTINE; RITONAVIR; RITONAVIR PLUS TIPRANAVIR; SIMEPREVIR;

AMINO ACID SUBSTITUTION; ANTIVIRAL ACTIVITY; DRUG APPROVAL; DRUG COST; DRUG EFFICACY; DRUG METABOLISM; DRUG SOLUBILITY; FATIGUE; GENOTYPE; HEADACHE; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; HYPERBILIRUBINEMIA; INSOMNIA; MULTICENTER STUDY (TOPIC); NAUSEA; NONHUMAN; NOTE; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSE; TREATMENT DURATION;

EID: 84926301951     PISSN: 10521372     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (28)

1. Wilkins T, Malcolm JK, Raina D, Schade RR. Hepatitis C: diagnosis and treatment. Am Fam Physician 2010;81(11):1351–1357.
2. World Health Organization. Hepatitis C: fact sheet number 164. April 2014. Available at: http://www.who.int/mediacentre/factsheets/fs164/en. Accessed November 28, 2014.
3. Centers for Disease Control and Prevention. Hepatitis C FAQs for the public. December 9, 2014. Available at: http://www.cdc.gov/hepatitis/c/CFAQ.htm. Accessed December 9, 2014.
4. Issur M, Gotte M. Resistance patterns associated with HCV NS5A inhibitors procontinued on page 276 vide limited insight into drug binding. Viruses 2014;6(11):4227–4241.
5. Poordad F, McCone J Jr, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011;364(13):1195–1206.
6. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011;364(25):2405–2416.
7. Food and Drug Administration. FDA approves first combination pill to treat hepatitis C. October 10, 2014. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm418365.htm. Accessed November 28, 2014.
8. Food and Drug Administration. FDA approves Viekira Pak to treat hepatitis C. December 19, 2014. Available at: http://www.fda.gov/NewsEvents/Newsroom/ PressAnnouncements/ucm427530.htm. Accessed March 2, 2015.
9. Viekira Pak (ombitasvir/paritaprevir/ritonavir and dasabuvir) prescribing information. North Chicago, Illinois: AbbVie Inc., February 2015.
10. Pawlotsky JM. NS5A inhibitors in the treatment of hepatitis C. J Hepatol 2013:59(2):375–382.
11. Sovaldi (sofosbuvir) prescribing information. Foster City, California: Gilead Sciences, Inc., November 2014.
12. Sofia MJ. Beyond sofosbuvir: What opportunity exists for a better nucleoside/ nucleotide to treat hepatitis C? J Antiviral 2014;107:119–124.
13. Harvoni (ledipasvir/sofosbuvir) prescribing information. Foster City, California: Gilead Sciences, Inc., October 2014.
14. German P, Pang P, West S, et al. Drug interactions between direct acting antiHCV antivirals sofosbuvir and ledipasvir and HIV antiretrovirals. Presentation at the 15th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy, Washington, DC, May 19–21, 2014.
15. German P, Yang J, West S, et al. Effect of food and acid reducing agents on the relative bioavailability and pharmacokinetics of ledipasvir/sofosbuvir fixed-dose combination tablet. Presentation at the 15th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy, Washington, DC, May 19–21, 2014.
16. Gao M. Antiviral activity and resistance of HCV NS5A replication complex inhibitors. Curr Opin Virol 2013;3(5):514–520.
17. Vermehren J, Sarrazin C. The role of resistance in HCV treatment. Best Pract Res Clin Gastroenterol 2012:26(4):487–503.
18. Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014;370(20):1889–1898.
19. Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014;370(16):1483–1493.
20. Kowdley KV, Gordon SC, Reddy KR, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 2014:370(20):1879–1888.
21. Gane EJ, Stedman CA, Hyland RH, et al. Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor ledipasvir or the NS5B non-nucleoside inhibitor GSn9669 against HCV genotype 1 infection. Gastroenterol 2014:146(3):736– 743.
22. Red Book Online. Ann Arbor, Michigan; Truven Health Analytics. Accessed March 5, 2015.
23. Langreth R. Hepatitis drug prices fall so low, no exclusives needed. Bloomberg Business. January 12, 2015. Available at: http://www.bloomberg.com/news/ articles/2015-01-12/prime-covers-bothgilead-and-abbvie-liver-drugs-as-pricesplunge. Accessed March 2, 2015.
24. Wasserman E. Gilead blazes ahead in hep C pricing battle with two new PBM deals. FiercePharma. Available at: http://www. fiercepharma.com/story/gilead-blazesahead-hep-c-pricing-battle-two-new-pbmdeals/2015-01-16. Accessed March 2, 2015.
25. American Association for the Study of Liver Diseases, Infectious Diseases Society of America, International Antiviral Society–USA. Recommendations for testing, managing, and treating hepatitis C. Available at: http://www.hcvguidelines.org. Accessed December 19, 2014.
26. Feld JJ, Kowdley KV, Coakley E, et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014;370(17):1594–1603.
27. Ferenci P, Bernstein D, Lalezari J, et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med 2014;370(21):1983–1992.
28. Poordad F, Hezode C, Trinh R, et al. ABT 450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med 2014;370(21):1973–1982.